Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of talquetamab combinations versus daratumumab + pomalidomide + dexamethasone in relapsed or refractory multiple myeloma
2023-503467-41-00Phase 3Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 18
01
Overview
Phase 3, randomised, open-label trial of talquetamab, daratumumab and pomalidomide in multiple myeloma (MM) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Progression-free survival. Planned start Oct 2022; status: authorised.
02
Drugs
talquetamabdaratumumabpomalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2023-503467-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503467-41-00.